AB0995 Vertebral fractures cascade: potential etiologies and risk factors. (12th June 2018)

• Record Type: Journal Article
• Authors: Che, H.; Breuil, V.; Cortet, B.; Paccou, J.; Chapuis, L.; Debiais, F.; Javier, R.M.; Mehsen Cetre, N.; Loiseau Peres, S.; Thomas, T.; Roux, C.; Briot, K.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1618
• Page End: 1618
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.2543
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Vertebral fracture (VF) is the most common osteoporotic fracture, and a strong risk factor of subsequent vertebral fracture. Prospective studies have shown that a recent VF increases an imminent risk of a subsequent one, and attention has been paid recently to a possible cascade phenomenon i.e. the occurrence of multiples VFs in less than one year. Objectives: This cascade could have severe consequences, and we prompted a study to identify potential causes of osteoporosis and risk factors. Methods: Vertebral fractures cascade (VFC) observations were collected retrospectively between January 2016 and April 2017. VFC was defined as the occurrence of at least 3 vertebral fractures within one year. Patients with other etiologies than osteoporosis (i.e. malignant or traumatic VFs) were excluded. The cause of osteoporosis associated with VFC was the one retained by the physician at the time of diagnosis. Results: Ninety-five observations of VFC (80% of women, mean age of 71 years) were collected in 10 centres (9 tertiary centres and 1 outpatient centre). The median number of incident VFs over 1 year was 4. 3–11 Forty-five patients (45.9%) had a previous major fracture before the VFC and 65 (70.7%) had densitometric osteoporosis (T-Score ≤−2.5 SD either at lumbar or femoral site). Eighteen (19%) patients currently received oral glucocorticoids treatment at the time of VFC, with a mean daily dose of 20 mg. Thirty-three (35.1%) patients received systemic glucocorticoids in the past. The main comorbidities were history of cancer (n=19) and chronic inflammatory diseases (n=21) including asthma (n=7), chronic obstructive pulmonary disease (n=7) and rheumatoid arthritis (n=7). A secondary osteoporosis associated with the cascade was diagnosed in 54 patients (54.5%) with the following causes: glucocorticoid-induced osteoporosis (n=22, 23.7%), benign hemopathies (mastocytosis, MGUS) (n=7, 7.1%), use of aromatase inhibitors (n=3, 3.1%), anorexia nervosa (n=3, 3.1%), alcoholism (n=3, 3.1%), pregnancy and lactation-associated osteoporosis (n=2, 2.1%), primary hyperparathyroidism (n=2, 2.1%) and hypercorticism (n=1, 1.1%). In addition, 11 cases (11.3%) were reported following a vertebroplasty procedure. Primary either postmenopausal or idiopathic osteoporosis was diagnosed in 48 patients (51.6%). A total of 29 (29.6%) patients previously received an anti-osteoporotic treatment. In six patients (6.3%), VFC occurred early (in the year) following discontinuation of an anti-osteoporotic treatment: 5 after denosumab and one 12 months after an infusion of zoledronic acid. Conclusions: The results of this retrospective study show that almost half of VFC occurred in patients with secondary osteoporosis. While they suggest that a careful management has to be given to these patients in order to prevent VFC in these circumstances, prospective studies are needed to further explore the determinants of such a severe complication of osteoporosis. Disclosure of Interest: None declared